Get the Daily Brief
Latest Biotech News
Pfizer sues to block Metsera‑Novo deal — obesity M&A turns litigious
Pfizer filed litigation seeking to enforce its merger agreement with Metsera and to block a competing offer tied to Novo Nordisk, accusing Novo and Metsera’s board of breaching contractual terms...
TScan cuts 30% of staff, halts solid‑tumor TCR program
TScan Therapeutics laid off roughly 30% of its workforce and stopped its Phase 1 solid‑tumor T‑cell receptor (TCR) trial to concentrate resources on blood‑cancer programs. The company cited a...
FDA leadership in flux: CDER director George Tidmarsh placed on leave
Reports indicate George Tidmarsh, director of the FDA’s Center for Drug Evaluation and Research (CDER), has been placed on administrative leave. Multiple outlets reported the move and cited...
Intellia clinical hold–dosing paused after severe liver injury
Intellia Therapeutics halted dosing and screening across its Phase III MAGNITUDE program and a second Phase III trial after a participant developed severe liver injury that met Hy’s law criteria....
Thermo Fisher shells out $9 billion: buys Clario to plug clinical‑data gap
Thermo Fisher Scientific agreed to acquire Clario in a deal valued at about $9 billion, expanding its clinical‑trial software and data-management capabilities. Clario provides endpoint data...
FDA turmoil...CDER director placed on leave as agency faces leadership strain
Reports indicate George Tidmarsh, director of the FDA’s Center for Drug Evaluation and Research (CDER), has been placed on administrative leave amid internal controversies. The moves were reported...
Amgen Ventures backs AAVantgarde: $141 million to accelerate retinal gene therapies
AAVantgarde closed a $141 million Series B led by Amgen Ventures to advance gene therapies for inherited retinal diseases that cause blindness. The Milan‑based company said the financing will fund...
Moderna unravels: vaccine success fails to translate into broader pipeline wins
Moderna is undergoing deep restructuring after Covid‑era revenue declines and unmet expectations for next‑generation mRNA programs. The company has cut costs, faced canceled government contracts...
Optical genome mapping augments CLL workup: pilot shows broader structural variant capture
Researchers piloted optical genome mapping (OGM) alongside FISH analysis to improve diagnostic resolution in chronic lymphocytic leukemia (CLL). The study showed OGM can detect structural variants...
Plasma pTau217 test: Fujirebio aims to speed Alzheimer’s diagnosis with blood assay
Fujirebio presented data on its Lumipulse G pTau217/β‑Amyloid 1‑42 plasma ratio test, positioning the assay to shorten diagnostic timelines for Alzheimer’s disease by providing accessible...
Phage tech moves from farms to clinics: virus‑loaded patches and bird‑flu phage research advance
Researchers developed microneedle patches that deliver bacteriophages into food to kill pathogens like E. coli and Salmonella, offering a potential on‑product safety measure for ready‑to‑eat...
AI and digital twins reshape R&D: binding‑affinity models and factory simulations scale discovery
New AI models for predicting binding affinity—exemplified by Boltz‑2—and advances in digital‑twin technologies are accelerating drug discovery and industrial bioprocessing. Boltz‑2 delivers fast,...
Tumor‑activated therapy and Cas9 delivery advances push next‑gen oncology tools
Seekyo Therapeutics reported preclinical progress on a Tumor Activated Therapy (SKY01) that leverages albumin binding and tumor‑microenvironment enzyme activation to release a cytotoxic payload...
Amgen backs Milan gene-therapy play: AAVantgarde raises $141M
AAVantgarde closed a $141 million Series B led in part by Amgen Ventures to advance gene therapies for inherited retinal diseases. The Milan-based biotech will deploy capital toward programs...
Intellia paused: FDA places clinical hold after serious liver event
Intellia voluntarily paused dosing and screening in its Phase III MAGNITUDE trial and a second Phase III study after a patient experienced Grade 4 transaminase elevations and hyperbilirubinemia...
Thermo Fisher spends $9B to add clinical-trial software: Clario deal
Thermo Fisher Scientific agreed to buy Clario for about $9 billion, acquiring software that captures, manages and analyzes clinical-trial endpoint data. The acquisition complements Thermo Fisher’s...
FDA leadership in flux: CDER director George Tidmarsh placed on leave
Reports indicate George Tidmarsh, director of the FDA’s Center for Drug Evaluation and Research (CDER), has been placed on leave. Multiple outlets report the move follows internal concerns;...
Pfizer drags Metsera to court as Novo enters fray—obesity race intensifies
Pfizer sued Metsera and Novo Nordisk in Delaware’s Court of Chancery seeking to block Metsera from accepting Novo’s counteroffer and to enforce a previously agreed buyout. Pfizer had bid roughly...
Moderna’s post‑pandemic reset: contracts cut, restructuring and pressure
A detailed review of Moderna’s business shows the company grappling with slumping Covid vaccine sales, canceled government contracts and major cuts to workforce and spending plans. Washington...
Bird-flu spillovers push phage therapy and vaccine research forward
The ongoing H5N1 avian influenza outbreaks, which have killed hundreds of millions of birds and spilled into multiple mammalian species, have renewed interest in bacteriophage therapeutics and...